InvestSMART

Bio-Gene Technology Ltd (ASX: BGT) - Share Price

- Current share price for BGT : $0.015

Bio-Gene Technology Ltd (BGT) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across crop protection, grain storage, public health and consumer uses.

BGT General Information +

ASX Code BGT
Website N/A
Industry/Sector Fertilizers & Agricultural Chemicals
Market Cap ($M) 6
BGT Share Price $0.015
Day High $0.015
Day Low $0.015
Last Close $0.015
BGT Share Price Movement - ( No change )
Prices as at 12:15, 19 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Bio-Gene Technology Ltd (BGT) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Bio-Gene Technology Ltd (BGT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Bio-Gene Technology Ltd (BGT) price-sensitive announcements

BGT - Quarterly Activities/Appendix 4C Cash Flow Report
Bio-Gene Technology Limited’s Quarterly Activities Report and Appendix 4C for the quarter
Bio-Gene Technology Ltd (BGT)
30 Oct 2026 | 9:16 AM
BGT - Appendix 4E and 2026 Annual Report
Bio-Gene Technology Limited’s Appendix 4E and 2026 Annual Report for the Australian financ
Bio-Gene Technology Ltd (BGT)
28 Aug 2026 | 12:13 PM
BGT - Quarterly Activities/Appendix 4C Cash Flow Report
Bio-Gene Technology Limited, an Australian agtech company, reported its quarterly activiti
Bio-Gene Technology Ltd (BGT)
31 Jul 2026 | 11:25 AM
BGT - Results of Placement
Bio-Gene Technology Ltd has announced a successful capital raising of $3.21 million throug
Bio-Gene Technology Ltd (BGT)
26 May 2026 | 9:59 AM

Bio-Gene Technology Ltd (BGT) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Bio-Gene Technology Ltd (BGT)
ORDINARY FULLY PAID
Materials $7 Notice of Annual General Meeting/Proxy Form 30 Oct 2026 11:22AM $0.013 $0.015 risen by 15.38%
Bio-Gene Technology Ltd (BGT)
ORDINARY FULLY PAID
Materials $7 Quarterly Activities/Appendix 4C Cash Flow Report 30 Oct 2026 9:16AM $0.013 $0.015 risen by 15.38%
Bio-Gene Technology Ltd (BGT)
ORDINARY FULLY PAID
Materials $7 Proposed issue of securities - BGT 28 Oct 2026 10:56AM $0.017 $0.015 fallen by 11.76%
Bio-Gene Technology Ltd (BGT)
ORDINARY FULLY PAID
Materials $7 Bio-Gene Receives $343,000 R&D Tax Incentive 19 Oct 2026 9:59AM $0.013 $0.015 risen by 15.38%
Bio-Gene Technology Ltd (BGT)
ORDINARY FULLY PAID
Materials $7 Date of 2026 Annual General Meeting 12 Oct 2026 9:20AM $0.014 $0.015 risen by 7.14%
Bio-Gene Technology Ltd (BGT)
ORDINARY FULLY PAID
Materials $7 Flavocide efficacy results against deer ticks published 7 Oct 2026 10:21AM $0.016 $0.015 fallen by 6.25%

BGT Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$2.33 -$0.80 -38.50% 0.00 0.00 0.00% 0.0%
2025A -$2.58 -$1.20 -6.20% 0.00 0.00 0.00% 0.0%
2024A -$2.41 -$1.30 -29.70% 0.00 0.00 0.00% 0.0%

BGT Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Bio-Gene Technology Ltd (BGT) $7M -0.3852 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Nufarm Limited (NUF) $1,284M 1.6328 -0.4381 1.6365 27.3995 48.7591 18.4939 0.00% 0.00% 1.48%

BGT Directors

Name Position Start Date
Mr Peter May Research & Development, Executive Director 29 May 2015
Mr Owen Timothy Grogan Chief Executive Officer, Managing Director 28 Aug 2023
Mr Andrew Wallace Guthrie Non-Executive Director 26 Apr 2021
Mr Christopher Mark Ramsey Non-Executive Director 12 May 2023
Mr Alex Huong Soo Ding Non-Executive Director, Non-Executive Chairman 12 May 2023

Bio-Gene Technology Ltd (BGT) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
10 Aug 2026 GUTHRIE, Andrew Issued Indirect Shares 200,000 $0.025 $5,000.000
10 Aug 2026 GROGAN, Owen Issued Indirect Shares 200,000 $0.025 $5,000.000
10 Aug 2026 RAMSEY, Christopher Issued Indirect Shares 200,000 $0.025 $5,000.000

See all changes in directors' interest & trades for Bio-Gene Technology Ltd (BGT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

BGT Management

Name Position
Drew Speedy Chief Financial Officer,Company Secretary

BGT Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Bio-Gene Technology Ltd (BGT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
58,011,245 (13.24%) Dr Choon Huat Lee
34,122,081 (7.79%) Vana Belle Pty Ltd
29,109,174 (6.65%) Mark Chang

BGT Calendar of Events

Date Event
27 August 2027 Report (Annual)
27 August 2027 Report (Prelim)
23 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.